UK Stock Market Today: FTSE 100 Futures Climb On Retail Resilience And Inflation Test

UK equities look set for a firmer open, with FTSE 100 futures in positive territory, as investors focus squarely on an awkward mix of higher domestic prices and slightly better retail activity. Sentiment leans cautiously optimistic rather than euphoric. The key driver is UK shop price inflation picking up to 2.1% year on year in October, the fastest pace since February 2024. At the same time, the CBI retail sales gauge has improved to -10 from -55, its strongest level in 18 months. Rising shop prices point to lingering cost pressure for retailers through transport, energy, employment and packaging, which keeps the risk of sticky inflation alive and influences Bank of England thinking on borrowing costs. A stabilising retail backdrop helps earnings resilience, yet cost pass through capacity remains uneven across the sector. The open hinges on a simple question. Does the Bank of England treat faster shop price inflation as noise from supply costs or as evidence that price pressure is reaccelerating just as demand shows faint signs of stabilising? Stocks to Watch Before the Opening Bell RHI Magnesita has updated the market on a possible offer for Vesuvius, with the deadline to announce firm intentions pushed out to 24 November 2026. A headline agreement on disposal revenue thresholds linked to potential antitrust remedies and a reverse break fee gives clearer guardrails. Attention now sits on regulatory risk and the stance of other large shareholders. The potential Vesuvius bid keeps RHI Magnesita in focus. Management has confirmed the extended timetable to 24 November 2026 and outlined agreement on disposal revenue thresholds tied to any antitrust remedies plus a reverse break fee. Support from Cevian Capital, Vesuvius’ largest shareholder, matters for deal momentum. Investors will watch funding plans and any update on expected synergies. HSBC is folding Hang Seng Bank’s asset management arm, which runs about US$50b, into HSBC Asset Management, a business overseeing roughly US$876b. The aim is to create a single, larger platform while keeping Hang Seng Bank as a separate licensed institution. The group also plans job cuts in UK wealth management linked to AI driven efficiency, which could reshape its cost base and product mix.
• Vistry Group (LSE:VTY) gained 8.23% as investors reacted to Helen Miles being named incoming Chief Financial Officer.
• Reckitt Benckiser Group (LSE:RKT) fell 4.85% after trimming its 2026 sales growth outlook and reporting softer third quarter revenue.
• Pearson (LSE:PSON) declined 3.43% following its agreement with CPA Canada to develop new digital learning content.
• Trainline (LSE:TRN) declined 3.42% after a recent analyst downgrade to Hold that cited regulatory concerns around ticket retail rules. For UK investors, the next few sessions are focused on heavyweight domestic bank and energy earnings alongside US central bank decisions and inflation data.
• Standard Chartered, Wed 28 Oct. Q3 2026 results land before the UK open. Any shift in net interest income or fee momentum will feed straight into how investors think about profitability across the internationally focused UK banking stocks.
• GSK, Wed 28 Oct. Third quarter numbers at 7:00 AM UTC put vaccine and specialty medicines sales under the microscope. Any change in research and development spend will guide how investors treat future cash generation in the wider UK pharma space.
• Shell, Thu 29 Oct. Q3 2026 figures arrive as oil prices respond to Middle East supply concerns. Capital expenditure plans and shareholder distributions will matter for how you weigh oil exposure within the FTSE 100.
• Lloyds Banking Group, Thu 29 Oct. When Lloyds reports Q3 2026 at 7:00 AM UTC, the shape of net interest margins and any update on mortgage book quality will help frame sentiment around UK consumer credit and housing-exposed lenders.
• US Federal Reserve Interest Rate Decision, Wed 28 Oct. A move relative to the current 4% policy rate, or a change in tone in the accompanying FOMC statement, would influence the dollar and in turn affect sterling, global risk appetite and FTSE 100 multinationals. Banks have slipped over the past week and month even though the wider Financials sector shows a small gain over the year. HSBC’s profit rise and fresh buyback have not stopped UK bank shares from coming under pressure as investors focus on how long strong interest income can last. For holders of bank stocks, the US Federal Reserve rate decision this evening is the main global cue because it can shift funding costs, the dollar and appetite for UK financials. Oil and Gas has edged higher over seven days and across the past month, helped by firmer crude prices in response to Middle East supply worries. At the same time, UK specific headlines around the Rosebank field and Ithaca Energy’s warning on future UK spending show how political decisions can sit alongside commodity moves in driving returns. The clearest trigger next is today’s US crude inventory data, which often sways oil prices and with them UK listed producers and fuel costs. Real Estate has risen over the past week and month, doing better than the slightly softer GB Market over seven days. Groups such as Primary Health Properties are selling assets into joint ventures and using proceeds to trim debt, which shows that many landlords still treat leverage as the main risk to manage rather than rent levels. For anyone holding REITs or housebuilders, Thursday’s Bank of England mortgage approvals numbers are the key read across to housing demand and how stretched household finances look. Pharmaceuticals & Biotech has moved higher over the past week and month, supported by a series of positive trial and approval headlines. AstraZeneca has seen new EU approval for Enhertu in early breast cancer, while Scancell is planning a global Phase 3 melanoma study that relies on the same broad idea of pairing vaccines with checkpoint drugs. For healthcare investors, the next thing to watch is company commentary with GSK’s results this morning because any detail on R&D and pricing plans can shape how the wider UK pharma sector is viewed. Tech has gained over the last seven days and remains one of the stronger areas year to date, even as Semiconductors have given back part of a very large earlier rise. Kainos features again in reports about rising demand for Workday and AI heavy consulting projects, which underlines how much spending is tied to cloud and automation plans rather than UK consumer demand. The next meaningful signal is tonight’s US Federal Reserve decision, since changes in global borrowing costs can quickly alter how investors treat higher growth, higher multiple sectors like UK technology. How To Find Stocks That Fit Your Strategy If you want bank and energy earnings to matter more than headlines, start building a watchlist with this list of list of solid balance sheet and fundamentals (207 results). This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com…Read more by Sasha Jovanovic